- Home
- GPAT vs RCKT Comparison
GPAT vs RCKT Comparison
Compare GPAT & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPAT
- RCKT
- Stock Information
- Founded
- GPAT 2020
- RCKT 1999
- Country
- GPAT United States
- RCKT United States
- Employees
- GPAT N/A
- RCKT N/A
- Industry
- GPAT
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- GPAT
- RCKT Health Care
- Exchange
- GPAT NYSE
- RCKT Nasdaq
- Market Cap
- GPAT 379.9M
- RCKT 328.6M
- IPO Year
- GPAT 2024
- RCKT N/A
- Fundamental
- Price
- GPAT $10.56
- RCKT $2.99
- Analyst Decision
- GPAT
- RCKT Buy
- Analyst Count
- GPAT 0
- RCKT 13
- Target Price
- GPAT N/A
- RCKT $14.79
- AVG Volume (30 Days)
- GPAT 47.8K
- RCKT 3.2M
- Earning Date
- GPAT 01-01-0001
- RCKT 08-12-2025
- Dividend Yield
- GPAT N/A
- RCKT N/A
- EPS Growth
- GPAT N/A
- RCKT N/A
- EPS
- GPAT 0.36
- RCKT N/A
- Revenue
- GPAT N/A
- RCKT N/A
- Revenue This Year
- GPAT N/A
- RCKT N/A
- Revenue Next Year
- GPAT N/A
- RCKT $591.46
- P/E Ratio
- GPAT $29.66
- RCKT N/A
- Revenue Growth
- GPAT N/A
- RCKT N/A
- 52 Week Low
- GPAT $10.00
- RCKT $2.19
- 52 Week High
- GPAT $10.64
- RCKT $24.27
- Technical
- Relative Strength Index (RSI)
- GPAT N/A
- RCKT 45.83
- Support Level
- GPAT N/A
- RCKT $3.00
- Resistance Level
- GPAT N/A
- RCKT $3.36
- Average True Range (ATR)
- GPAT 0.00
- RCKT 0.20
- MACD
- GPAT 0.00
- RCKT 0.02
- Stochastic Oscillator
- GPAT 0.00
- RCKT 30.38
About GPAT GP-ACT III ACQUISITION CORP
GP-Act III Acquisition Corp is a blank check company.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.